On Tuesday, Ligand Pharmaceuticals, Inc (NASDAQ: LGND) opened higher 3.86% from the last session, before settling in for the closing price of $147.01. Price fluctuations for LGND have ranged from $93.58 to $151.55 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 16.03% at the time writing. With a float of $19.09 million, this company’s outstanding shares have now reached $19.41 million.
In an organization with 68 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 88.81%, operating margin of -18.27%, and the pretax margin is -45.04%.
Ligand Pharmaceuticals, Inc (LGND) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ligand Pharmaceuticals, Inc is 2.58%, while institutional ownership is 96.44%. The most recent insider transaction that took place on Aug 01 ’25, was worth 61,586. In this transaction Director of this company sold 467 shares at a rate of $131.88, taking the stock ownership to the 45,989 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director proposed sale 467 for $131.00, making the entire transaction worth $61,177.
Ligand Pharmaceuticals, Inc (LGND) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted 1.84 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 1.35) by 0.49. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.98 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.03% per share during the next fiscal year.
Ligand Pharmaceuticals, Inc (NASDAQ: LGND) Trading Performance Indicators
Check out the current performance indicators for Ligand Pharmaceuticals, Inc (LGND). In the past quarter, the stock posted a quick ratio of 5.21. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.95. Likewise, its price to free cash flow for the trailing twelve months is 56.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.00, a number that is poised to hit 1.84 in the next quarter and is forecasted to reach 7.16 in one year’s time.
Technical Analysis of Ligand Pharmaceuticals, Inc (LGND)
Let’s dig in a bit further. During the last 5-days, its volume was 0.73 million. That was better than the volume of 0.15 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 86.12%.
During the past 100 days, Ligand Pharmaceuticals, Inc’s (LGND) raw stochastic average was set at 93.90%, which indicates a significant increase from 85.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 5.88 in the past 14 days, which was higher than the 4.50 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $123.63, while its 200-day Moving Average is $114.68. However, in the short run, Ligand Pharmaceuticals, Inc’s stock first resistance to watch stands at $156.48. Second resistance stands at $160.27. The third major resistance level sits at $164.01. If the price goes on to break the first support level at $148.95, it is likely to go to the next support level at $145.21. Assuming the price breaks the second support level, the third support level stands at $141.42.
Ligand Pharmaceuticals, Inc (NASDAQ: LGND) Key Stats
There are currently 19,294K shares outstanding in the company with a market cap of 2.99 billion. Presently, the company’s annual sales total 167,130 K according to its annual income of -4,030 K. Last quarter, the company’s sales amounted to 47,630 K and its income totaled 4,850 K.
